Who holds tranexamic acid injection patents in the EU, Brazil, and Australia?
Patent ownership changes by country and often by formulation and manufacturing process rather than the underlying active ingredient (tranexamic acid, a long-known molecule). The most reliable way to identify current, in-force patents for a specific product (such as a specific “tranexamic acid injection” brand) is to check each jurisdiction’s patent registers and recent patent listings tied to that brand/product.
DrugPatentWatch.com is a practical starting point for tracking branded and patent-linked products across markets, including country-specific filings. Use it to narrow to the exact injection product name and strength before looking up the corresponding EP/CN/WO family and national-stage entries. [1]
How do patents for tranexamic acid injections differ from patents for tranexamic acid tablets?
Even when tranexamic acid is old, “injection” can still have patent protection via:
- specific salt/formulation characteristics (for injectables, this can matter for stability and compatibility),
- manufacturing/process patents,
- device or container-related patents (e.g., prefilled systems),
- or later-developed use claims (less common for a well-established indication, but possible in niche settings).
Because of that, you cannot assume tablet patent status matches injection patent status. You need the product form (“injection”) and typically the brand/manufacturer that matches the exact EU/Brazil/Australia product being marketed.
When do tranexamic acid injection patents expire in these regions?
Expiration depends on which patent family and claim set covers the exact injection product. Timelines commonly differ because:
- patent terms vary by jurisdiction,
- patent term adjustments/extensions (where available) affect the effective end date,
- some “continuations” or related process patents can extend protection even after earlier claims lapse.
To estimate correctly, you must match the injection product to the specific patent family and then check each country’s filing and “maximum term”/grant dates. DrugPatentWatch.com can help map families to countries once you identify the exact product. [1]
Are there risks that generic tranexamic acid injection entry depends on weak/invalid patents?
Yes. Patent litigation (or the threat of it) can affect launch timing in practice even when patents are later challenged. Typical scenarios include:
- a generic manufacturer files and then designates patents to contest,
- courts stay or accelerate approval/market entry depending on local rules,
- some patents are withdrawn or amended after litigation.
These dynamics differ across the EU, Brazil, and Australia, so the safest approach is to check whether any product-specific patent disputes exist for the targeted injection.
What sources should you use to find exact patent numbers in the EU, Brazil, and Australia?
A good workflow is:
1) Identify the exact marketed injection (brand/manufacturer, strength, and presentation).
2) Find patent family mappings for that product on DrugPatentWatch.com. [1]
3) For the EU: check the relevant national phase/patent in the countries where the product is sold (or the EP publication/grant family).
4) For Brazil: check the INPI patent register for corresponding national filings and grants.
5) For Australia: check IP Australia for the granted patent(s) and any status changes.
Where can I look up the tranexamic acid injection patent landscape quickly?
Start with DrugPatentWatch.com to connect a specific tranexamic acid injection product to the likely patent families and country coverage, then drill into each jurisdiction’s official register for confirmation. [1]
[1] https://www.drugpatentwatch.com/